Trials In Focus

Inside Stories – Asian trial growth creates hurdles
Despite rapid growth in clinical trial activity across Asia, sponsors and CROs need to take care in managing unfamiliar environments says the CEO of Australian-based CRO, Novotech.
Alek Safarian told the 46th annual meeting of the Drug Information Association (DIA) in Washington DC last week that regulatory complexity [...]

Novotech announces four country Asia expansion at AusBiotech 2009

NOVOTECH ANNOUNCES FOUR COUNTRY ASIA EXPANSION AT AUSBIOTECH 2009
New operations in Malaysia, Singapore, Thailand, and Philippines
Sydney, Oct 27, 2009 – Leading Australian contract clinical research company Novotech announced today that it was expanding into four new Asian markets with the establishment of a management hub in Kuala Lumpur, Malaysia.
Novotech CEO Alek Safarian said the time [...]

BioTechnology News

Novotech expands presence in Asia

Unlisted Australian contract research organisation Novotech is continuing its aggressive Asian expansion plans, announcing yesterday it will establish a regional management hub in Malaysia and a presence in Singapore, Thailand and the Philippines.
Novotech, which has had a bumper year despite the economic downturn, according to chief executive Alek Safarian, will [...]

Trials In Focus

New Asia hub for Novotech

Australian-based CRO Novotech is expanding into four new Asian markets with the establishment of a management hub in Kuala Lumpur. The hub will cover Novotech’s presence in Singapore, Thailand and the Philippines, adding to a joint venture presence in India and an office in Korea.
“A sizeable patient population, transparent regulatory environment, [...]

Novotech wins coveted Australian CRO Award from Frost & Sullivan

San Diego, CA– June 19, 2008 — Novotech, the largest Australian owned contract
research organization (CRO) has confirmed its position as the pre-eminent Australian
based CRO with the award by leading industry analyst house Frost & Sullivan as the
Australian CRO of the Year. The award is part of the prestigious Excellence in
Healthcare Awards series covering a spectrum [...]

Athletes, and non-athletes, between 18 and 65 wanted for tinea study

ATHLETES’ FOOT AFFECTS MORE THAN 9% OF PEOPLE
Sydney, Australia – November 17, 2007 – A novel new oral treatment for Tinea, commonly known as Athletes’ Foot, is now being tested by Australian research teams in Melbourne, Sydney, Adelaide and Brisbane as part of a global study in the condition that affects over 9% [...]

Australian research teams test prawn shell treatment to combat hayfever

“DRUG FROM THE SEA” SHOWS POTENTIAL FOR ALLERGY SUFFERERS
Sydney, Australia – November 14, 2007 – A novel agent for the treatment of rhinitis, commonly known as hayfever, is now being tested by Australian research teams in Melbourne, Sydney, and Brisbane. The agent is derived from the shells of marine crustaceans.
Dr Rimmer from the Woolcock Institute [...]

Novotech in expansion mode as CRO sector continues to grow at 15%

BioPacificVentures and Co-Investor Capital Partners invest in Novotech and back expansion plans
Sydney, Australia, Orange County, CA – October 21, 2007 — Novotech, the largest Australian owned contract research organization (CRO) with offices on the US east and west coasts, is now in rapid expansion mode as the CRO sector fundamentals continue to strengthen with growth [...]

Novotech alerts Pharma and Biotechs at DIA 2007 to Australias new R&D tax break that applies to clinical trials

New Tax break comes into effect July 1, 2007
Atlanta, GA – July 1, 2007 — Novotech, the largest Australian owned contract research organization (CRO) with offices on the US east and west coasts, announced on the eve of DIA 2007 that the new tax breaks for research in Australia, which includes clinical trials, starts July [...]

Novotech says Australia ideally placed to become Bioequivalence trials hub

Sydney, Australia, May 15, 2007 — Novotech, the largest independent Australian owned contract research organization (CRO) with expertise in TGA/EMEA/FDA registration said today Australia should aggressively market its bioequivalence trials capabilities overseas and take a large share of the multi-billion dollar sector. Already more than 70% of Novotech’s bioequivalence work comes from offshore, according to [...]

Next Page »